Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Period	Debt/Equity
2016-06-30	6.86
2017-06-30	7.73
2018-06-30	6.79
2019-06-30	7.79
2020-06-30	6.71
2021-06-30	5.97
2022-06-30	7.89
2023-06-30	7.93
2024-06-30	9.39
2025-06-30	4.79

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARAY	$0.46	+2.63%	1.05M
3
4
5

Accuray Incorporated (ARAY) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Accuray Incorporated Data in Excel

More ARAY Financial Data